🔐

GenMedMD

enter passkey to continue

incorrect passkey

← SequenceMedicine
Physician Resource

Genomic Medicine,
Clinical Clarity

Evidence-based decision support for integrating genetic testing into everyday clinical practice. Know when to test, what to order, and how to act on results.

Explore Clinical Pathways

Why Genomic Medicine Now

Genetic testing has moved from research curiosity to clinical necessity. The evidence, accessibility, and diagnostic power are here. The question is no longer whether to integrate genomics, but how quickly.

~53%
Average Diagnostic Yield

Across 20 organ systems, exome and genome sequencing delivers a molecular diagnosis in roughly half of appropriately selected patients, far exceeding most imaging and laboratory workups.

5-7 yr
Diagnostic Odyssey

The average rare disease patient sees 7+ specialists over 5 to 7 years before receiving a diagnosis. A single genetic test can collapse that timeline to weeks.

80%
Management Change Rate

In pediatric and cardiac ICU settings, 80% of positive genomic diagnoses directly change the clinical management plan, from medication adjustments to surgical decisions.

$250
Starting Cost per Test

Clinical-grade exome sequencing now starts at $250 to $3,000, making definitive molecular diagnosis cost-competitive with a single MRI or specialist consultation.

Clinical Pathways by Specialty

Structured workflows for determining when genetic testing is indicated, selecting the right test, and interpreting results within the clinical context of each specialty.

❤️

Cardiovascular Genetics

Diagnostic yield: 32-67%

Guideline-based testing pathways for heritable cardiomyopathies, arrhythmia syndromes, aortopathies, and familial hypercholesterolemia. Cascade screening algorithms for at-risk family members.

HCM / DCM Long QT Brugada FH
🧠

Neurogenetics

Diagnostic yield: 43-58%

Testing algorithms for unexplained epilepsy, hereditary neuropathies, movement disorders, and leukodystrophies. Rapid sequencing pathways for neonatal-onset neurological presentations.

Epilepsy CMT Ataxia Dystonia Leukodystrophy
🔬

Oncogenomics

Diagnostic yield: varies by tumor type

Germline and somatic testing workflows for hereditary cancer syndromes, tumor profiling for therapy selection, and pharmacogenomic guidance for chemotherapy dosing and adverse event prevention.

BRCA1/2 Lynch Li-Fraumeni PGx
🫀

Renal Genetics

Diagnostic yield: 46-81%

Diagnostic algorithms for steroid-resistant nephrotic syndrome, unexplained CKD in young adults, CAKUT, cystic kidney diseases, and genetic tubulopathies. Early diagnosis enables targeted management and transplant planning.

Alport CAKUT PKD FSGS Nephrolithiasis
👶

Pediatrics & NICU

Diagnostic yield: 34-59%

Rapid genome sequencing protocols for critically ill neonates and children with multiple congenital anomalies or unexplained developmental delay. Median turnaround of 3 to 7 days with documented reductions in length of stay.

Rapid WGS MCA DD/ID NBS follow-up

Built for Practicing Physicians

Practical tools and resources designed for clinicians who need to make genomic decisions at the point of care, not in a research lab.

🧭

Decision Support

Indication-specific algorithms that guide you from clinical suspicion to the right genetic test, with clear criteria for when sequencing adds value over traditional workup.

📊

Testing Algorithms

Step-by-step workflows for test selection across 20 organ systems, including when to choose panels, exome, or genome sequencing, and how to handle variants of uncertain significance.

📖

Interpretation Guides

Plain-language frameworks for reading genetic test reports, understanding pathogenicity classifications, and translating molecular findings into actionable clinical decisions.

🎓

CME Resources

Continuing medical education modules covering genomic fundamentals, specialty-specific applications, and emerging evidence, designed for physicians at any level of genetic literacy.

Grounded in Published Clinical Data

80
Peer-reviewed references
20
Organ systems characterized
30M
Americans with rare diseases
$1T
Annual U.S. burden